Client News

Destiny Pharma receives award from the Cystic Fibrosis Foundation

Heidelberg Pharma Reports on First Half-Year 2022

Andera Partners strengthens its Life Sciences team with a new partner

Destiny Pharma announces publication of XF-73 drug synergy data

Carbios, On, Patagonia, PUMA and Salomon team up to advance circularity in the textile industry

InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

Destiny Pharma announces start of a new XF-73 research programme

Newron extends Senior Management team and strengthens commitment to ESG

Element drives global life science strategy with appointment of industry expert Dr. Elisabeth Lackner as Chief Scientific Officer

InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19